Medication Aims to Improve Moderate COVID-19 Symptoms

Trial Objective

Medication Aims to Improve Moderate COVID-19 SymptomsThis study is to find out if an investigational drug, called dapansutrile, safely and effectively improves symptoms of moderate COVID-19. Researchers also want to know if dapansutrile shortens the time that a patient is sick with COVID-19. To qualify, participants must have tested positive for COVID-19 and have experienced their first symptoms of the virus within five days of becoming part of the study. Half of the participants in this trial will receive the medication and half of the participants will receive a placebo, which looks like the drug but has no medication. The medication or placebo will be taken twice a day for 14 days.

Enrollment

Active Clinical Trials Currently Recruiting

Who Can Participate

People who have tested positive for COVID-19 and have experienced their first symptoms of the virus within five days of becoming a participant in the study, who also have a fever and shortness of breath may be eligible for the study.

Age: 18+    Gender: Any Gender


Estimated Time Commitment

Up to 45 days

While taking the medication or placebo, participants will be asked to come into the clinic on days 1, 4, 8 and 15. Participants will be asked to complete two phone calls with researchers on day 29 and day 45.



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Christopher Houser
303.398.1911

Cole Waliczek

Cole Waliczek
303.270.2844

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Olatec Therapeutics LLC

Principal Investigators


Request More Information

Complete this form to learn more about this study and see if you qualify.


*
*
*
*